SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: Dementia - Pipeline Review, H2 2012: Plan Mergers and Acquisitions Effectively By Identifying Players of the Most Promising Pipeline

[January 14, 2013]

Research and Markets: Dementia - Pipeline Review, H2 2012: Plan Mergers and Acquisitions Effectively By Identifying Players of the Most Promising Pipeline

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/wrvp9r/dementia) has announced the addition of Global Markets Direct's new report "Dementia - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Dementia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dementia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dementia. Dementia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC (News - Alert) filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the globl therapeutic scenario for Dementia.


- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Dementia pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Dementia.

- Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned:

Abbott Laboratories

GlaxoSmithKline plc

Sylentis

Astellas Pharma Inc.

Eisai Co., Ltd.

Kowa Company, Ltd.

Merz GmbH & Co. KGaA

Neuren Pharmaceuticals Limited

ProteoTech, Inc.

The University of Tokyo

WhanIn Pharmaceutical Co., Ltd.

SYGNIS Pharma AG

Allon Therapeutics Inc.

MediPost Co., Ltd.

e-Therapeutics plc

Oryzon

TauRx Therapeutics Ltd

Acumen Pharmaceuticals, Inc.

BIOALVO S.A.

IMMD Inc.

Neurimmune Therapeutics AG

BioArctic Neuroscience AB

Intellect (News - Alert) Neurosciences, Inc.

Sparsha Pharma International Pvt. Ltd.

Tautatis Incorporated

Stelic Institute & Co.

Varinel, Inc.

For more information visit http://www.researchandmarkets.com/research/wrvp9r/dementia

Source (News - Alert): Global Markets Direct


[ Back To education 's Homepage ]








Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved | Privacy Policy